Quest for the right Drug
פלוטיפורם 50/5 FLUTIFORM 50/5 (FLUTICASONE PROPIONATE, FORMOTEROL FUMARATE DIHYDRATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
שאיפה : INHALATION
צורת מינון:
תרחיף בלחץ לשאיפה : PRESSURISED SUSPENTION FOR INHALATION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Interactions : אינטראקציות
4.5 Interaction with other medicinal products and other forms of interaction No formal drug interaction studies have been performed with Flutiform inhaler. Flutiform inhaler contains sodium cromoglicate at non-pharmacological levels. Patients should not discontinue any cromoglicate containing medication. Fluticasone propionate, an individual component of Flutiform inhaler, is a substrate of CYP 3A4. Co-treatment with CYP 3A inhibitors (e.g. ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nelfinavir, saquinavir, ketoconazole, telithromycin, cobicistat) is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects. The ECG changes and/or hypokalaemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β agonists, especially when the recommended dose of the β agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the co-administration of a β agonist with non-potassium sparing diuretics. Xanthine derivates and glucocorticosteroids may add to a possible hypokalaemic effect of the β agonists. In addition L-Dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards β2 sympathomimetics. Concomitant treatment with monoamine oxidase inhibitors, including agents with similar properties such as furazolidone and procarbazine, may precipitate hypertensive reactions. There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons. Concomitant use of other β adrenergic drugs can have a potentially additive effect. Hypokalaemia may increase the risk of arrhythmias in patients who are treated with digitalis glycosides. Formoterol fumarate, as with other β2 agonists, should be administered with caution to patients being treated with tricyclic antidepressants or monoamine oxidase inhibitors, and during the immediate two week period following their discontinuation, or other drugs known to prolong the QTc interval such as antipsychotics (including phenothiazines), quinidine, disopyramide, procainamide, and antihistamines. Drugs that are known to prolong the QTc interval can increase the risk of ventricular arrhythmias (see section 4.4). If additional adrenergic drugs are to be administered by any route, they should be used with caution, because the pharmacologically predictable sympathetic effects of formoterol may be potentiated. Beta adrenergic receptor antagonists (β blockers) and formoterol fumarate may inhibit the effect of each other when administered concurrently. Beta blockers may also produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with β blockers and this includes β blockers used as eye drops for treatment of glaucoma. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of β blockers in patients with asthma. In this setting, cardioselective β blockers could be considered, although they should be administered with caution.
מסגרת הכללה בסל
התוויות הכלולות במסגרת הסל
התוויה | תאריך הכללה | תחום קליני | Class Effect | מצב מחלה |
---|---|---|---|---|
אסטמה | ||||
אסטמה | ||||
אסטמה | ||||
אסטמה | ||||
אסטמה | ||||
אסטמה | ||||
אסטמה | ||||
אסטמה | ||||
אסטמה | ||||
אסטמה |
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
12/01/2014
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף
עלון מידע לצרכן
08.08.22 - עלון לצרכן אנגלית 08.08.22 - עלון לצרכן עברית 08.08.22 - עלון לצרכן ערבית 07.06.23 - עלון לצרכן עברית 12.02.24 - עלון לצרכן עברית 05.04.24 - עלון לצרכן אנגלית 05.04.24 - עלון לצרכן עברית 05.04.24 - עלון לצרכן ערבית 29.03.21 - החמרה לעלון 19.04.21 - החמרה לעלון 07.06.23 - החמרה לעלון 12.02.24 - החמרה לעלוןלתרופה במאגר משרד הבריאות
פלוטיפורם 50/5